Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB
Saudi Arabian Osteoporosis Drugs Market
Dublin, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia Osteoporosis Drugs Market to Reach US$ 308.84 Million by 2033 - 4.33% CAGR Driven by Biologics and Aging Population" report has been added to ResearchAndMarkets.com's offering.The Saudi Arabia Osteoporosis Drugs Market is expected to reach US$ 308.84 million by 2033 from US$ 210.89 million in 2024, with a CAGR of 4.33% from 2025 to 2033
Due to improved healthcare infrastructure, the Saudi Arabian market for osteoporosis medications is concentrated in urban areas like Riyadh, Jeddah, and Dammam, whereas rural areas have less access to experts, diagnostics, and treatment alternatives.
Growing rates of osteoporosis, the quick uptake of biologics, and advantageous healthcare laws in a number of Saudi Arabian nations are the main causes of this expansion. While bisphosphonates continue to dominate in volume due to their cost effectiveness, the biologics segment is anticipated to grow at the quickest rate. Government programs under Vision 2030, which prioritize regional medication production and improved healthcare infrastructure, promote the pharmaceutical industry. Osteoporosis treatments are becoming more accessible and reasonably priced as a result of these initiatives, and both name brand and generic medications are essential in satisfying the rising demand.Bisphosphonates, calcitonin, parathyroid hormone analogs, selective estrogen receptor modulators (SERMs), and monoclonal antibodies are among the available treatments. Newer biologic medicines are steadily gaining traction because of their increased efficacy and better patient outcomes, even if bisphosphonates are still frequently administered. Despite progress, issues like poor drug adherence, low awareness in rural regions, and underdiagnosis still exist.
Additionally, comprehensive nationwide screening programs and coordinated post fracture care are lacking. Reducing the long term economic cost of osteoporosis in the nation and improving treatment outcomes could be achieved by addressing these challenges through integrated care models, digital health technologies, and education.Key Factors Driving the Saudi Arabia Osteoporosis Drugs Market Growth
Saudi Arabia's Aging Population Is GrowingBecause osteoporosis and aging are closely related, Saudi Arabia's aging population is a major factor driving up demand for osteoporosis medications. People are more susceptible to fractures, loss of bone density, and associated problems as they get older, especially those over?60. The need for long term therapeutic treatments as well as preventive measures is growing as a result of this demographic shift.
More people are reaching the age range where osteoporosis becomes a major concern due to better healthcare and longer life expectancies. As a result, the incidence of osteoporosis is rising in areas with greater populations of elderly persons. In order to assist the aging population and lessen the health burden associated with fractures, this development emphasizes the urgent need for efficient drugs and healthcare measures.Higher Rates of Screening and DiagnosisEarly osteoporosis identification has increased throughout Saudi Arabia thanks to the availability of sophisticated diagnostic technologies including dual energy X ray absorptiometry (DEXA) and bone mineral density (BMD) scanning. These technologies are now widely used in hospitals and clinics, increasing screening accessibility for high risk populations, especially postmenopausal women. In order to encourage early testing and diagnosis, health authorities are aggressively promoting awareness and screening initiatives.
Because of this, more people are being diagnosed with bone loss early on, when treatment can be most successful. The number of patients eligible for osteoporosis treatments has increased dramatically due to the increase in early detection, which has increased demand for pharmacological interventions and made it possible to control the condition more effectively over the long term.Government Initiated Medical ProgramsAs a national health issue, osteoporosis is being actively addressed by the Saudi Arabian government. It seeks to lower the frequency of fractures and enhance bone health outcomes through education programs, public health campaigns, and preventative measures. Osteoporosis screening and bone density monitoring are becoming more commonplace in national health programs, and access to therapies is being facilitated by drug reimbursement policies and subsidized treatment options.
These programs are promoting earlier medical intervention and increasing treatment adherence. Additionally, by making strategic investments in public health, the government's Vision 2030 push for local pharmaceutical development and a larger healthcare infrastructure is bolstering the availability of osteoporosis medications and promoting long term market growth.Challenges in the Saudi Arabia Osteoporosis Drugs Market
Low Persistence and Adherence to TreatmentLow patient adherence and persistence with prescribed medication regimens is one of the main issues facing Saudi Arabia's osteoporosis management. A lack of immediate, apparent benefits, worries about long term health repercussions, or worries about adverse effects cause many patients to stop treatment too soon. Non-adherence is also influenced by cultural norms and a lack of knowledge about how osteoporosis progresses.
Treatment results are harmed as a result, raising the risk of fractures and associated problems. Long term patient involvement is challenging for healthcare practitioners, particularly when patients need daily or weekly oral medication. Enhancing patient education, providing alternate dosage regimens, and incorporating follow up assistance may all contribute to increased adherence and improved population wide therapeutic efficacy.Poor Treatment Persistence and AdherencePoor patient perseverance and adherence to prescribed treatment regimens is one of the main issues facing osteoporosis care in Saudi Arabia. Due to worries about side effects, worries about long term health repercussions, or a lack of obvious, immediate advantages, many patients stop treatment too soon. Non-adherence is further exacerbated by cultural attitudes and a lack of knowledge regarding the progressive nature of osteoporosis.
Treatment results suffer as a result, and the risk of fractures and associated complications rises. It can be challenging for healthcare professionals to stay in touch with patients over the long term, particularly when they need daily or weekly oral medication. Enhancing follow up assistance, providing alternate dose schedules, and improving patient education may all contribute to increased adherence and improved therapeutic efficacy for the general public.
Company Analysis: Overview, Key Persons, Recent Developments, SWOT Analysis, Revenue Analysis
Amgen Inc.
Eli Lilly and Company
F. Hoffmann La Roche AG
GlaxoSmithKline Plc
Merck & Co. Inc.
Novartis AG
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
UCB S.A.
Key Attributes:
Report Attribute
Details
No. of Pages
200
Forecast Period
2024 - 2033
Estimated Market Value (USD) in 2024
$210.89 Million
Forecasted Market Value (USD) by 2033
$308.84 Million
Compound Annual Growth Rate
4.3%
Regions Covered
Saudi Arabia
Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Saudi Arabia Osteoporosis Drugs Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Product Type6.2 By Route of Administration6.3 By States7. Product Type7.1 Bisphosphonates7.2 Calcitonin7.3 Rank Ligand Inhibitor7.4 Parathyroid Hormone Therapy (PTH)7.5 Selective Estrogen Receptor Modulators (SERMs)7.6 Sclerostin Inhibitor7.7 Others8. Route of Administration8.1 Oral8.2 Injectable8.3 Others9. Top States9.1 Dhahran9.2 Riyadh9.3 Khobar9.4 Jeddah9.5 Dammam9.6 Others10. Value Chain Analysis11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Competition11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threats13. Pricing Benchmark Analysis13.1 Amgen Inc.13.2 Eli Lilly and Company13.3 F. Hoffmann-La Roche AG13.4 GlaxoSmithKline Plc13.5 Merck & Co. Inc.13.6 Novartis AG13.7 Pfizer Inc.13.8 Teva Pharmaceutical Industries Ltd.13.9 UCB S.A.14. Key Players Analysis
For more information about this report visit https://www.researchandmarkets.com/r/ly9ifi
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Saudi Arabian Osteoporosis Drugs Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Anterix Inc (ATEX) Q1 2026 Earnings Call Highlights: Strong Financial Position and Strategic ...
Cash Position: Approximately $41 million at the end of Q1 fiscal 2026. Contracted Proceeds: Approximately $140 million outstanding, with $70 million expected in fiscal 2026, mostly in Q4. Total Gain: $35 million, including $34 million from exchanging narrow bands for broadband licenses and $1 million from the sale of broadband licenses. Operating Expense Reduction: 20% reduction in operating expenses over the last year. Spectrum Clearing: Over 80% of incumbents cleared within the spectrum band, with licenses delivered or applicable in approximately 90% of U.S. counties. Warning! GuruFocus has detected 3 Warning Sign with ATEX. Release Date: August 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Anterix Inc (NASDAQ:ATEX) has launched an oversubscribed accelerator program with engagements exceeding $500 million in potential contract value, surpassing the initial $250 million of matching funds. The company is operating from a position of strong financial strength, ending Q1 debt-free with a healthy cash position of approximately $41 million. Anterix Inc (NASDAQ:ATEX) has achieved a 20% reduction in operating expenses, enhancing efficiency and capital flexibility. The company has cleared over 80% of incumbents within its spectrum band, allowing for broadband licenses in approximately 90% of all U.S. counties. Seven utilities are deploying 900 megahertz private LTE at scale, representing the fifth largest wireless network footprint in the U.S., validating the technology's effectiveness. Negative Points The stock price does not reflect the company's progress and market enthusiasm, indicating a disconnect between perceived and actual value. There is uncertainty regarding the timing of gains from narrowband to broadband license exchanges due to dependency on FCC approvals. The strategic alternatives process is active but passive, suggesting limited immediate opportunities for significant strategic partnerships or acquisitions. One utility dropped out of the demonstrated intent scorecard, although the company maintains it hasn't lost any opportunities. The company faces challenges in aligning the timing of spectrum clearing and license applications with utility customer requests, impacting revenue recognition. Q & A Highlights Q: With roughly 10% of narrowband broadband license exchanges remaining, what's the potential gain when that happens, and does it change if you get a five-by-five report in order? A: (Timothy Gray, CFO) We have the ability to apply for broadband licenses in 90% of U.S. counties. Gains from these licenses should represent over $1 billion over time, appearing in the income statement as we obtain them. The timeline for these gains depends on the FCC's approval process and utility customer requests. Q: What happens to the spectrum when utilities drop out of the pipeline in a region? A: (Ryan Gerbrandt, COO) We haven't lost anything. The change in the demonstrated intent scorecard reflects personnel changes at utilities, not a loss of opportunity. We continue to build relationships with new utility executives to maintain momentum. Q: How do you address the dichotomy between an oversubscribed accelerator program and a stock price that doesn't reflect that? A: (Scott Lang, CEO) The lack of announcements doesn't mean a lack of progress. Utilities are methodical, and these contracts, which are substantial, take time. The value of our assets and the uniqueness of our offering are significant, and the first seven customers have de-risked the process for future customers. Q: Are utilities in the accelerator program viewing this as a scarce resource? A: (Scott Lang, CEO) Yes, utilities see it as a scarce resource and are eager to engage. The alternatives are costly, and our proven value proposition is compelling. We have allocated appropriate funds to support these engagements. Q: Is the strategic alternatives process active or on the back burner? A: (Scott Lang, CEO) It's active but passive in terms of serious negotiations due to our current valuation. The strategic value of our solution is recognized, and discussions are ongoing with parties interested in participating in our journey. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
14 minutes ago
- Yahoo
Gold Holds Gain After Bessent Urges Fed to Slash Interest Rates
(Bloomberg) -- Gold held a small gain after traders increased bets the Federal Reserve will cut interest rates next month, following pressure from US Treasury Secretary Scott Bessent. Bullion rose as much as 0.6% on Thursday before paring gains to trade near $3,365 an ounce. Prices saw a modest increase in the previous session, supported by a fall in Treasury yields after Bessent suggested the Fed's benchmark rate ought to be at least 1.5 percentage points lower than it is now. Lower borrowing costs and declining yields tend to support gold, as it pays no interest. The US-Canadian Road Safety Gap Is Getting Wider Sunseeking Germans Face Swiss Backlash Over Alpine Holiday Congestion To Head Off Severe Storm Surges, Nova Scotia Invests in 'Living Shorelines' Five Years After Black Lives Matter, Brussels' Colonial Statues Remain For Homeless Cyclists, Bikes Bring an Escape From the Streets The increased bets on monetary easing mark a shift from last month, when markets at one point saw less than a 50% chance of a September rate cut. The consensus is now for a quarter-point move next month, with some betting on a larger reduction. Gold has climbed 28% this year, with the bulk of those gains occurring in the first four months. It has been supported by heightened geopolitical and trade tensions that have spurred haven demand, while central bank purchases have also underpinned its strength. Spot gold was up 0.2% to $3,363.35 an ounce at 8:14 a.m. in London, after rising 0.2% in the previous session. The Bloomberg Dollar Spot Index was steady. Silver and platinum were little changed, while palladium edged higher. The market is still seeking official clarification over whether US imports of gold bars would be subject to tariffs, after days of confusion that prompted a spike in the premium for gold futures in New York over the spot price in London. President Donald Trump said on Monday that there would not be a levy — causing the two markets to converge — but he didn't elaborate. Americans Are Getting Priced Out of Homeownership at Record Rates Dubai's Housing Boom Is Stoking Fears of Another Crash Why It's Actually a Good Time to Buy a House, According to a Zillow Economist Bessent on Tariffs, Deficits and Embracing Trump's Economic Plan The Electric Pickup Truck Boom Turned Into a Big Bust ©2025 Bloomberg L.P.
Android Authority
15 minutes ago
- Android Authority
These displays are banned in US, and here's how it affects Pixel 10 and iPhone 17
Joe Maring / Android Authority TL;DR The International Trade Commission has decided to ban BOE's OLED screens from the US. However, a display expert says companies like Apple and Google can still sell devices with BOE screens in the US. The ruling could adversely affect the repair market, though. The International Trade Commission (ITC) recently ruled that it would ban display maker BOE's OLED screens from the US market. The ban, which isn't final, could see BOE banned from the country for almost 15 years. But what does this mean for smartphone makers like Apple, Google, and others that use BOE displays? Display analyst Ross Young noted on Twitter that the ban could have 'little impact' on brands like Apple and Google as they'd still be able to sell their phones in the US. Check out the tweet below. Unfortunately, Young adds that this ban would hurt the repair market. That's bad news for consumers, as it means they might not have recourse in the event of a broken phone screen. Even if you can get your display fixed in the first place, a limited supply of replacement screens could theoretically lead to much higher screen repair costs. This could be particularly problematic for upcoming phone releases, as manufacturers and repair agents might not have the chance to stockpile replacement screens. Don't want to miss the best from Android Authority? Set us as a preferred source in Google Search to support us and make sure you never miss our latest exclusive reports, expert analysis, and much more. We also asked OnePlus earlier this week about the ramifications of a BOE ban in the US. However, the company refused to comment on the matter. If Young's claims hold true, though, then OnePlus doesn't necessarily have to worry about OnePlus 15 sales. Either way, this preliminary display ban might not affect sales of smartphones with BOE screens. So I don't anticipate sales issues with the Pixel 10 series or iPhone 17 range. But you should probably invest in a durable case and a screen protector. Follow
